Clinical Observation of Shengmaiyin,Wuling SAN,and Noxintol for Heart Failure
Objective:The therapeutic impact of Shengmaiyin,Wuling SAN,and Noxintol in treating heart failure(HF).Methods:96 HF patients from October 2020 to October 2021 in the hospital were randomly divided into control group(n=48)and observation group(n=48).Both groups got cardiotonic,diuretic,vasodilator and other basic treatments.The control group received nosintol,while the observation group received Shengmaiyin,Wuling SAN and nosintol.Clinical effectiveness,heart function changes before and after therapy,and adverse prognostic responses of two groups were compared.Results:After 4 weeks of treatment,the effective treatment rate in the observation group was significantly higher than that in the control group,and the difference was statistically significant(x2=4.042,P＜0.05).After treatment,the left ventricular function indexes LVEDD and LVESD in the observation group were significantly lower than those in the control group,with statistically significant difference(t=5.244,4.542;P＜0.05).During the treatment period,no serious adverse reactions occurred in the two groups.The incidence of adverse reactions such as nausea and vomiting,dizziness and fatigue,diarrhea and skin allergy was not statistically significant(x2=1.043、0.344、0.340、0、0.801,P＞0.05).According to the analysis of logistics regression model,both patient age and heart rate were influential factors for drug safety(OR=0.392、0.916,P＜0.05).Conclusion:Shengmaiyin,Wuling SAN and Noxintol can significantly improve the overall curative effect of HF patients.
Heart failureShengmaiyin combined with Wuling SANNoxintoxilHeart function
万方数据
维普
